Given that apoA5 is a liver-specific protein, we initially speculated that olanzapine-induced reduction of plasma apoA5 levels could be a consequence of decreased hepatic apoA5 production, leading to hypertriglyceridemia. The gene discussed is APOA5; the disease is hypertriglyceridemia.